ImmunityBio, Inc. IBRX
$6.92
▼ -1.39% 24H
About
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees680
TickerIBRX
Statistics
Market Cap$7.25B
Revenue (TTM)$113.3M
Net Income-$351.4M
Net Margin-310.2%
EPS$-0.38
P/E-18.92
P/S53.86
P/B-8.49
EV/EBITDA-33.98
ROE70.3%
Dividend Yield—
Price$6.92
Data: Twelve Data · Revenue = mcap / P/S